智通财经APP获悉,1月2日,NMPA官网显示,GSK(GSK.US)的IL-5单抗美泊利珠单抗注射液(mepolizumab,Nucala)的新适应症上市申请已获批准,推测此次获批的适应症为慢性鼻窦炎伴鼻息肉。
慢性鼻窦炎伴鼻息肉是一种鼻道内壁或鼻窦的慢性炎症性疾病,可导致称为鼻息肉的软组织生长,通常以嗜酸性粒细胞水平升高为特征。由此产生的肿胀可能会在两个鼻孔(双侧)中生长,由于各种症状,包括鼻塞、嗅觉丧失、面部压力和鼻涕,对患者产生巨大影响。对于严重病例,可能需要手术治疗。然而,息肉有很强的复发倾向,通常会导致重复手术。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.